Published in Mol Immunol on February 07, 2006
A Brief Review on Diagnosis of Foot-and-Mouth Disease of Livestock: Conventional to Molecular Tools. Vet Med Int (2011) 1.19
Insertional protein engineering for analytical molecular sensing. Microb Cell Fact (2006) 0.87
Discriminating foot-and-mouth disease virus-infected and vaccinated animals by use of beta-galactosidase allosteric biosensors. Clin Vaccine Immunol (2009) 0.77
Effects of rosiglitazone on the liver histology and mitochondrial function in ob/ob mice. Hepatology (2007) 2.14
Protein quality in bacterial inclusion bodies. Trends Biotechnol (2006) 2.02
Unfinished stories on viral quasispecies and Darwinian views of evolution. J Mol Biol (2010) 2.00
Amyloid-like properties of bacterial inclusion bodies. J Mol Biol (2005) 1.90
Protein folding and conformational stress in microbial cells producing recombinant proteins: a host comparative overview. Microb Cell Fact (2008) 1.89
Aggregation as bacterial inclusion bodies does not imply inactivation of enzymes and fluorescent proteins. Microb Cell Fact (2005) 1.79
[Diagnosis and treatment of bronchiectasis. Spanish Society of Pneumology and Thoracic Surgery]. Arch Bronconeumol (2008) 1.75
HIV-1 reverse transcriptase inhibitor resistance mutations and fitness: a view from the clinic and ex vivo. Virus Res (2008) 1.70
Microbial factories for recombinant pharmaceuticals. Microb Cell Fact (2009) 1.59
Discovery of a novel polyomavirus in acute diarrheal samples from children. PLoS One (2012) 1.48
The conformational quality of insoluble recombinant proteins is enhanced at low growth temperatures. Biotechnol Bioeng (2007) 1.34
Recombinant protein solubility - does more mean better? Nat Biotechnol (2007) 1.21
Localization of functional polypeptides in bacterial inclusion bodies. Appl Environ Microbiol (2006) 1.20
Divergent genetic control of protein solubility and conformational quality in Escherichia coli. J Mol Biol (2007) 1.18
IL28B SNP rs8099917 is strongly associated with pegylated interferon-α and ribavirin therapy treatment failure in HCV/HIV-1 coinfected patients. PLoS One (2010) 1.17
Role of molecular chaperones in inclusion body formation. FEBS Lett (2003) 1.16
Sequence homology required by human immunodeficiency virus type 1 to escape from short interfering RNAs. J Virol (2006) 1.12
Localization of chaperones DnaK and GroEL in bacterial inclusion bodies. J Bacteriol (2005) 1.12
HIV-1 protease catalytic efficiency effects caused by random single amino acid substitutions. Mol Biol Evol (2006) 1.10
Learning about protein solubility from bacterial inclusion bodies. Microb Cell Fact (2009) 1.09
Nanotechnology, bionanotechnology and microbial cell factories. Microb Cell Fact (2010) 1.09
Biomedical applications of distally controlled magnetic nanoparticles. Trends Biotechnol (2009) 1.08
Bacterial inclusion bodies: making gold from waste. Trends Biotechnol (2011) 1.07
Fitness landscape of human immunodeficiency virus type 1 protease quasispecies. J Virol (2006) 1.06
Unconventional microbial systems for the cost-efficient production of high-quality protein therapeutics. Biotechnol Adv (2012) 1.05
Isolation of cell-free bacterial inclusion bodies. Microb Cell Fact (2010) 1.05
Deciphering the interleukin 28B variants that better predict response to pegylated interferon-α and ribavirin therapy in HCV/HIV-1 coinfected patients. PLoS One (2012) 1.05
Biological role of bacterial inclusion bodies: a model for amyloid aggregation. FEBS J (2011) 1.01
Early HCV dynamics on Peg-interferon and ribavirin in HIV/HCV co-infection: indications for the investigation of new treatment approaches. AIDS (2004) 1.01
Folding of a misfolding-prone beta-galactosidase in absence of DnaK. Biotechnol Bioeng (2005) 1.01
Side effects of chaperone gene co-expression in recombinant protein production. Microb Cell Fact (2010) 1.01
Tunable geometry of bacterial inclusion bodies as substrate materials for tissue engineering. Nanotechnology (2010) 1.00
Yield, solubility and conformational quality of soluble proteins are not simultaneously favored in recombinant Escherichia coli. Biotechnol Bioeng (2008) 0.99
Epistasis among deleterious mutations in the HIV-1 protease. J Mol Biol (2009) 0.96
Nanostructured bacterial materials for innovative medicines. Trends Microbiol (2010) 0.95
Engineering building blocks for self-assembling protein nanoparticles. Microb Cell Fact (2010) 0.95
Assessing the use of the "opening angle method" to enforce residual stresses in patient-specific arteries. Ann Biomed Eng (2007) 0.95
The chaperone DnaK controls the fractioning of functional protein between soluble and insoluble cell fractions in inclusion body-forming cells. Microb Cell Fact (2006) 0.95
The Functional quality of soluble recombinant polypeptides produced in Escherichia coli is defined by a wide conformational spectrum. Appl Environ Microbiol (2008) 0.94
Combination of a mutagenic agent with a reverse transcriptase inhibitor results in systematic inhibition of HIV-1 infection. Virology (2005) 0.92
Membrane-active peptides for non-viral gene therapy: making the safest easier. Trends Biotechnol (2008) 0.91
Systems metabolic engineering, industrial biotechnology and microbial cell factories. Microb Cell Fact (2012) 0.90
Effect of the size and location of osteochondral defects in degenerative arthritis. A finite element simulation. Comput Biol Med (2006) 0.90
The nanoscale properties of bacterial inclusion bodies and their effect on mammalian cell proliferation. Biomaterials (2010) 0.90
Complete nucleotide sequence of genotype 4 hepatitis C viruses isolated from patients co-infected with human immunodeficiency virus type 1. Virus Res (2006) 0.90
Risk factors of emergency care and admissions in COPD patients with high consumption of health resources. Respir Med (2004) 0.89
Overexpression of the immunoreceptor CD300f has a neuroprotective role in a model of acute brain injury. Brain Pathol (2011) 0.89
Mutational patterns associated with the 69 insertion complex in multi-drug-resistant HIV-1 reverse transcriptase that confer increased excision activity and high-level resistance to zidovudine. J Mol Biol (2006) 0.89
Functional inclusion bodies produced in bacteria as naturally occurring nanopills for advanced cell therapies. Adv Mater (2012) 0.89
Modular protein engineering for non-viral gene therapy. Trends Biotechnol (2004) 0.88
Bacterial inclusion bodies are cytotoxic in vivo in absence of functional chaperones DnaK or GroEL. J Biotechnol (2005) 0.87
Protein nanodisk assembling and intracellular trafficking powered by an arginine-rich (R9) peptide. Nanomedicine (Lond) (2010) 0.87
Amyloid-linked cellular toxicity triggered by bacterial inclusion bodies. Biochem Biophys Res Commun (2007) 0.87
Insertional protein engineering for analytical molecular sensing. Microb Cell Fact (2006) 0.87
Role of the chaperone DnaK in protein solubility and conformational quality in inclusion body-forming Escherichia coli cells. FEMS Microbiol Lett (2007) 0.86
Catalytic efficiency and phenotype of HIV-1 proteases encoding single critical resistance substitutions. Virology (2002) 0.86
Peptide-mediated DNA condensation for non-viral gene therapy. Biotechnol Adv (2009) 0.86
Modular protein engineering in emerging cancer therapies. Curr Pharm Des (2009) 0.86
Influence of growth temperature on the production of antibody Fab fragments in different microbes: a host comparative analysis. Biotechnol Prog (2010) 0.86
Profiling the allosteric response of an engineered beta-galactosidase to its effector, anti-HIV antibody. Biochem Biophys Res Commun (2004) 0.85
Production of functional inclusion bodies in endotoxin-free Escherichia coli. Appl Microbiol Biotechnol (2014) 0.85
RNA interference as a tool for exploring HIV-1 robustness. J Mol Biol (2011) 0.85
Rehosting of bacterial chaperones for high-quality protein production. Appl Environ Microbiol (2009) 0.84
Post-production protein stability: trouble beyond the cell factory. Microb Cell Fact (2011) 0.84
A wide range of NS3/4A protease catalytic efficiencies in HCV-infected individuals. Virus Res (2007) 0.84
Biological activities of histidine-rich peptides; merging biotechnology and nanomedicine. Microb Cell Fact (2011) 0.83
In situ protein folding and activation in bacterial inclusion bodies. Biotechnol Bioeng (2008) 0.83
Lon and ClpP proteases participate in the physiological disintegration of bacterial inclusion bodies. J Biotechnol (2005) 0.83
Fast electrochemical detection of anti-HIV antibodies: coupling allosteric enzymes and disk microelectrode arrays. Anal Chim Acta (2009) 0.83
Internalization and kinetics of nuclear migration of protein-only, arginine-rich nanoparticles. Biomaterials (2010) 0.83
Neuroprotection from NMDA excitotoxic lesion by Cu/Zn superoxide dismutase gene delivery to the postnatal rat brain by a modular protein vector. BMC Neurosci (2006) 0.83
Integrating mechanical and biological control of cell proliferation through bioinspired multieffector materials. Nanomedicine (Lond) (2015) 0.82
Thymidine analogue resistance suppression by V75I of HIV-1 reverse transcriptase: effects of substituting valine 75 on stavudine excision and discrimination. J Biol Chem (2009) 0.82
Recombinant protein quality evaluation: proposal for a minimal information standard. Stand Genomic Sci (2011) 0.82
Inhibition of HIV-1 replication by RNA targeted against the LTR region. AIDS (2005) 0.82
Spontaneous improvement of the renal function in a patient with HIV-associated focal glomerulosclerosis. Am J Nephrol (2002) 0.82
Enhanced response to antibody binding in engineered beta-galactosidase enzymatic sensors. Biochim Biophys Acta (2002) 0.81
Peptide-assisted traffic engineering for nonviral gene therapy. Drug Discov Today (2008) 0.81
Engineering nuclear localization signals in modular protein vehicles for gene therapy. Biochem Biophys Res Commun (2003) 0.81
Strategies for the production of difficult-to-express full-length eukaryotic proteins using microbial cell factories: production of human alpha-galactosidase A. Appl Microbiol Biotechnol (2015) 0.81
Intracellular CXCR4⁺ cell targeting with T22-empowered protein-only nanoparticles. Int J Nanomedicine (2012) 0.81
DnaK/DnaJ-assisted recombinant protein production in Trichoplusia ni larvae. Appl Microbiol Biotechnol (2009) 0.80
Interleukin-10 overexpression does not synergize with the neuroprotective action of RGD-containing vectors after postnatal brain excitotoxicity but modulates the main inflammatory cell responses. J Neurosci Res (2011) 0.80
The impact of dnaKJ overexpression on recombinant protein solubility results from antagonistic effects on the control of protein quality. Biotechnol Lett (2004) 0.80
HLA class I protective alleles in an HIV-1-infected subject homozygous for CCR5-Δ32/Δ32. Immunobiology (2012) 0.80
Supramolecular organization of protein-releasing functional amyloids solved in bacterial inclusion bodies. Acta Biomater (2012) 0.80
Level of awareness of personnel in hospital services related to the donation process: A Spanish and Latin American multicenter study. J Heart Lung Transplant (2012) 0.80